Proper archiving of clinical study documents is an important practice for maintaining the quality, integrity, and usability of study data, and for ensuring regulatory compliance. These aspects are especially important in the context of RWE studies, where the scope and complexity of the regulatory requirements and standards, can differ significantly across and between regions. For example, here are some country-specific archiving timelines for observational drug studies:
Argentina = 2 years
Austria = 15 years
Brazil = 5 years
Germany = 10 years
Japan = 5 years
Netherlands = 15 years
South Korea = 3 years
Turkey = 5 years
According to ISPE GPP, where there are no specified national or regional requirements for retention of study materials, the archive should be maintained for at least five years after final report or first publication of study results, whichever comes later.
Additional considerations when determining what to archive and for how long, include:
[1] Legal Protection (Contractual Obligations): Archiving documents can offer protection in the event of legal questions or disputes related to the conduct of the study, data ownership, patient consent, adverse event reporting, etc. If you are a vendor, check study management contracts for any document retention obligations.
[2] Real-World Study Document Index (RWS-DI): The RWS-DI is a framework developed by a working group of real-world study (RWS) experts to address the challenges of filing essential documents for non-interventional and observational studies. Designed to be consistent with the TMF RM format and structure, but removes artifacts specific to clinical trials and replaces terminology such as “trial” with “study” and “subject” with “patient.”
In conclusion, the process of archiving clinical study documents should not be overlooked, especially in the arena of RWE studies. Regulatory compliance, data validation, legal protection, and future research potential hinge on the effective preservation of these important materials. As the rules can differ wildly from Argentina’s 2-year requirement to Austria and Netherlands’ 15 years, it’s critical to be aware of both regional specifics and overarching guidelines like the ISPE GPP’s five-year rule. Additionally, tools like the RWS-DI provide a specialized framework to ensure that archiving practices are tailored to the unique needs of RWE studies. So, when you’re next managing an observational study, remember – good archiving isn’t just about meeting regulations; it’s about safeguarding the integrity of your study, its results, and the future studies it may inspire.
Share this story...
Real World Evidence (RWE) 101 – Study Designs
RWE 101 - Study Designs Real-world evidence (RWE) studies are becoming increasingly important in healthcare decision-making. There are various study designs used to generate RWE, each with their unique [...]
Real World Evidence (RWE) 101 – Protocol Considerations
RWE 101 - Protocol Considerations Real-world evidence (RWE) study protocols and clinical trial protocols both outline the design and conduct of a study. However, they are distinctly different in [...]
Real World Evidence (RWE) 101 – PASS Approval Requirements
RWE 101 - PASS Approval Requirements Post-authorisation safety studies (PASS) are studies conducted after a medicine has been authorized (licensed) with the goal of acquiring more data about the [...]
Real World Evidence (RWE) 101 – Categories of PASS
RWE 101 - Categories of PASS Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a product derived from the analysis of [...]
Real World Evidence (RWE) 101 – Safety Monitoring
RWE 101 - Safety Monitoring Real World Evidence (RWE) complements clinical trials and provides additional insights that are difficult to achieve in controlled environments. Here's why:[1] Sample Size and [...]
Real World Evidence (RWE) 101 – How RWE is Being Used to Support the Treatment of Cancer
RWE 101 - How RWE is Being Used to Support the Treatment of Cancer Real-world evidence (RWE) enhances cancer treatment through providing more comprehensive and personalized patient data. Here [...]







